Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Ferrous-fumarate | hsa00030 | Pentose phosphate pathway | 2.93E-02 | 2 | P60891, P37837 | PRPS1, TALDO1 | More | | Ferrous-fumarate | hsa00052 | Galactose metabolism | 2.00E-02 | 3 | P08237, P19367, Q14376 | PFKM, HK1, GALE | More | | Ferrous-fumarate | hsa00220 | Arginine biosynthesis | 2.93E-02 | 2 | P05089, P49448 | ARG1, GLUD2 | More | | Ferrous-fumarate | hsa00230 | Purine metabolism | 3.16E-02 | 2 | P20839, Q16774 | IMPDH1, GUK1 | More | | Ferrous-fumarate | hsa00380 | Tryptophan metabolism | 2.05E-05 | 2 | Q16613, P46952 | AANAT, HAAO | More | | Ferrous-fumarate | hsa00532 | Glycosaminoglycan biosynthesis - chondroitin sulfate / dermatan sulfate | 1.24E-03 | 1 | Q9Y2C2 | UST | More | | Ferrous-fumarate | hsa00561 | Glycerolipid metabolism | 2.51E-02 | 2 | P51648, P23743 | ALDH3A2, DGKA | More | | Ferrous-fumarate | hsa00562 | Inositol phosphate metabolism | 7.30E-04 | 4 | P27987, Q96PE3, P19174, P42338 | ITPKB, INPP4A, PLCG1, PIK3CB | More | | Ferrous-fumarate | hsa00565 | Ether lipid metabolism | 1.25E-02 | 2 | Q9Y6K0, Q8N661 | CEPT1, TMEM86B | More | | Ferrous-fumarate | hsa00620 | Pyruvate metabolism | 2.51E-02 | 2 | P40925, P51648 | MDH1, ALDH3A2 | More | | Ferrous-fumarate | hsa00630 | Glyoxylate and dicarboxylate metabolism | 2.78E-03 | 2 | P40925, P15104 | MDH1, GLUL | More | | Ferrous-fumarate | hsa00785 | Lipoic acid metabolism | 1.84E-05 | 2 | O43766, Q9Y234 | LIAS, LIPT1 | More | | Ferrous-fumarate | hsa00830 | Retinol metabolism | 1.10E-03 | 2 | P11766, P00352 | ADH5, ALDH1A1 | More | | Ferrous-fumarate | hsa00860 | Porphyrin and chlorophyll metabolism | 6.63E-03 | 1 | Q16595 | FXN | More | | Ferrous-fumarate | hsa00970 | Aminoacyl-tRNA biosynthesis | 2.65E-02 | 1 | P14868 | DARS | More | | Ferrous-fumarate | hsa01100 | Metabolic pathways | 1.95E-03 | 37 | O43766, Q9Y234, P35790, Q16772, P30041, P15104, P51648, P19367, P42338, Q96PE3, P19174, Q14642, P27987, Q13370, P20839, P00918, P40925, Q9Y6K0, Q14376, P48506, P08237, P23743, O95861, P21399, P07101, Q9UHK6, P43034, Q86VZ5, P09917, P48651, Q9H4F1, Q53FZ2, P34059, P35573, Q969G6, P14927, Q13029 | LIAS, LIPT1, CHKA, GSTA3, PRDX6, GLUL, ALDH3A2, HK1, PIK3CB, INPP4A, PLCG1, INPP5A, ITPKB, PDE3B, IMPDH1, CA2, MDH1, CEPT1, GALE, GCLC, PFKM, DGKA, BPNT1, ACO1, TH, AMACR, PAFAH1B1, SGMS1, ALOX5, PTDSS1, ST6GALNAC4, ACSM3, GALNS, AGL, RFK, UQCRB, PRDM2 | More | | Ferrous-fumarate | hsa01200 | Carbon metabolism | 2.71E-02 | 4 | P37837, P60891, P11766, P49448 | TALDO1, PRPS1, ADH5, GLUD2 | More | | Ferrous-fumarate | hsa01210 | 2-Oxocarboxylic acid metabolism | 1.51E-02 | 2 | P21399, P50213 | ACO1, IDH3A | More | | Ferrous-fumarate | hsa01230 | Biosynthesis of amino acids | 3.05E-02 | 4 | P08237, P21399, P50213, P37837 | PFKM, ACO1, IDH3A, TALDO1 | More | | Ferrous-fumarate | hsa01521 | EGFR tyrosine kinase inhibitor resistance | 7.30E-04 | 4 | Q92529, P19174, P42338, Q9NRA1 | SHC3, PLCG1, PIK3CB, PDGFC | More | | Ferrous-fumarate | hsa01522 | Endocrine resistance | 3.67E-02 | 5 | P14780, P22694, Q9UM47, P46527, P10415 | MMP9, PRKACB, NOTCH3, CDKN1B, BCL2 | More | | Ferrous-fumarate | hsa02010 | ABC transporters | 2.65E-02 | 1 | P45844 | ABCG1 | More | | Ferrous-fumarate | hsa03013 | RNA transport | 3.03E-03 | 12 | P52298, Q09161, O14893, P61326, P37198, Q7Z3B4, P35658, Q14152, O75822, Q14240, Q9Y6A5, Q06787 | NCBP2, NCBP1, GEMIN2, MAGOH, NUP62, NUP54, NUP214, EIF3A, EIF3J, EIF4A2, TACC3, FMR1 | More | | Ferrous-fumarate | hsa03015 | mRNA surveillance pathway | 3.71E-02 | 6 | O43148, Q13362, O94913, Q12996, Q09161, P52298 | RNMT, PPP2R5C, PCF11, CSTF3, NCBP1, NCBP2 | More | | Ferrous-fumarate | hsa04010 | MAPK signaling pathway | 1.15E-02 | 9 | Q02750, Q15283, P09619, Q8IZS8, P54284, Q9H2K8, O43283, Q12933, P51812 | MAP2K1, RASA2, PDGFRB, CACNA2D3, CACNB3, TAOK3, MAP3K13, TRAF2, RPS6KA3 | More | | Ferrous-fumarate | hsa04012 | ErbB signaling pathway | 9.49E-03 | 3 | Q92529, P19174, P42338 | SHC3, PLCG1, PIK3CB | More | | Ferrous-fumarate | hsa04014 | Ras signaling pathway | 2.29E-04 | 7 | P42338, Q92529, Q9NRA1, P49767, P63218, P50151, P19174 | PIK3CB, SHC3, PDGFC, VEGFC, GNG5, GNG10, PLCG1 | More | | Ferrous-fumarate | hsa04015 | Rap1 signaling pathway | 3.91E-02 | 4 | Q9NRA1, P49767, P42338, P19174 | PDGFC, VEGFC, PIK3CB, PLCG1 | More | | Ferrous-fumarate | hsa04020 | Calcium signaling pathway | 2.16E-02 | 4 | P27987, P19174, Q9NRA1, P49767 | ITPKB, PLCG1, PDGFC, VEGFC | More | | Ferrous-fumarate | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 4.48E-02 | 5 | P09341, P19875, P25024, P25025, P14784 | CXCL1, CXCL2, CXCR1, CXCR2, IL2RB | More | | Ferrous-fumarate | hsa04062 | Chemokine signaling pathway | 3.76E-04 | 10 | P25024, P25025, P09341, P19875, P07948, P42338, P19174, Q92529, P63218, P50151 | CXCR1, CXCR2, CXCL1, CXCL2, LYN, PIK3CB, PLCG1, SHC3, GNG5, GNG10 | More | | Ferrous-fumarate | hsa04064 | NF-kappa B signaling pathway | 2.15E-02 | 7 | P14778, P19174, Q04759, P06239, P09341, P19875, Q06643 | IL1R1, PLCG1, PRKCQ, LCK, CXCL1, CXCL2, LTB | More | | Ferrous-fumarate | hsa04070 | Phosphatidylinositol signaling system | 3.19E-04 | 5 | P19174, P42338, P23743, Q96PE3, P27987 | PLCG1, PIK3CB, DGKA, INPP4A, ITPKB | More | | Ferrous-fumarate | hsa04071 | Sphingolipid signaling pathway | 4.14E-02 | 4 | Q16537, Q9BX95, Q16539, P04637 | PPP2R5E, SGPP1, MAPK14, TP53 | More | | Ferrous-fumarate | hsa04072 | Phospholipase D signaling pathway | 9.29E-05 | 9 | P42338, Q92529, P43657, P25024, P25025, P19174, Q14344, P23743, Q9NRA1 | PIK3CB, SHC3, P2RY5, CXCR1, CXCR2, PLCG1, GNA13, DGKA, PDGFC | More | | Ferrous-fumarate | hsa04137 | Mitophagy - animal | 3.24E-02 | 4 | Q96CV9, Q9H1Y0, P18848, O43524 | OPTN, ATG5, ATF4, FOXO3 | More | | Ferrous-fumarate | hsa04144 | Endocytosis | 4.65E-03 | 5 | O75351, P62491, Q14161, O75154, P49418 | VPS4B, RAB11A, GIT2, RAB11FIP3, AMPH | More | | Ferrous-fumarate | hsa04151 | PI3K-Akt signaling pathway | 2.55E-03 | 8 | P42338, Q9NRA1, P49767, P08238, P63218, P50151, O15335, P14784 | PIK3CB, PDGFC, VEGFC, HSP90AB1, GNG5, GNG10, CHAD, IL2RB | More | | Ferrous-fumarate | hsa04213 | Longevity regulating pathway - multiple species | 3.85E-02 | 4 | P42338, Q9Y4H2, P11142, Q13547 | PIK3CB, IRS2, HSPA8, HDAC1 | More | | Ferrous-fumarate | hsa04216 | Ferroptosis | 1.51E-02 | 3 | P04637, Q9H1Y0, P33121 | TP53, ATG5, ACSL1 | More | | Ferrous-fumarate | hsa04260 | Cardiac muscle contraction | 1.81E-04 | 4 | Q8IZS8, P54284, P09493, P14927 | CACNA2D3, CACNB3, TPM1, UQCRB | More | | Ferrous-fumarate | hsa04370 | VEGF signaling pathway | 1.56E-02 | 2 | P19174, P42338 | PLCG1, PIK3CB | More | | Ferrous-fumarate | hsa04371 | Apelin signaling pathway | 1.24E-02 | 4 | P63218, P50151, Q13370, Q14344 | GNG5, GNG10, PDE3B, GNA13 | More | | Ferrous-fumarate | hsa04510 | Focal adhesion | 1.55E-02 | 5 | P42338, O15335, Q9NRA1, P49767, Q92529 | PIK3CB, CHAD, PDGFC, VEGFC, SHC3 | More | | Ferrous-fumarate | hsa04520 | Adherens junction | 9.72E-03 | 5 | Q09472, P19784, P61586, P60709, P63261 | EP300, CSNK2A2, RHOA, ACTB, ACTG1 | More | | Ferrous-fumarate | hsa04610 | Complement and coagulation cascades | 5.02E-03 | 2 | P00734, P0C0L4 | F2, C4A | More | | Ferrous-fumarate | hsa04611 | Platelet activation | 4.11E-02 | 3 | P42338, Q14344, P07948 | PIK3CB, GNA13, LYN | More | | Ferrous-fumarate | hsa04613 | Neutrophil extracellular trap formation | 2.76E-02 | 10 | O60603, P05164, P08246, Q9UM07, Q6FI13, P14598, Q15080, P49913, O75015, P21462 | TLR2, MPO, ELA2, PADI4, H2AC18; H2AC19, NCF1, NCF4, CAMP, FCGR3B, FPR1 | More | | Ferrous-fumarate | hsa04621 | NOD-like receptor signaling pathway | 7.61E-03 | 10 | P25963, Q9H1Y0, O00463, P10415, Q05823, P01375, P49913, P59665, P59666, P12838 | NFKBIA, ATG5, TRAF5, BCL2, RNASEL, TNF, CAMP, DEFA1; DEFA1B, DEFA3, DEFA4 | More | | Ferrous-fumarate | hsa04640 | Hematopoietic cell lineage | 1.37E-02 | 7 | P14778, P27930, P11215, P25063, P07766, P01732, P09564 | IL1R1, IL1R2, ITGAM, CD24, CD3E, CD8A, CD7 | More | | Ferrous-fumarate | hsa04650 | Natural killer cell mediated cytotoxicity | 2.48E-03 | 8 | P19174, P06239, O60880, P20963, P42338, Q13241, P26718, O14931 | PLCG1, LCK, SH2D1A, CD247, PIK3CB, KLRD1, KLRK1, NCR3 | More | | Ferrous-fumarate | hsa04657 | IL-17 signaling pathway | 1.53E-02 | 6 | P25963, O00463, P14780, P80188, P01375, P06702 | NFKBIA, TRAF5, MMP9, LCN2, TNF, S100A9 | More | | Ferrous-fumarate | hsa04658 | Th1 and Th2 cell differentiation | 8.18E-06 | 8 | Q04759, P07766, P20963, P19174, P06239, Q9UL17, P14784, Q13761 | PRKCQ, CD3E, CD247, PLCG1, LCK, TBX21, IL2RB, RUNX3 | More | | Ferrous-fumarate | hsa04659 | Th17 cell differentiation | 9.15E-05 | 9 | Q04759, P19174, P06239, P14784, P14778, Q9UL17, P08238, P07766, P20963 | PRKCQ, PLCG1, LCK, IL2RB, IL1R1, TBX21, HSP90AB1, CD3E, CD247 | More | | Ferrous-fumarate | hsa04660 | T cell receptor signaling pathway | 3.37E-03 | 8 | Q04759, P42338, P19174, P07766, P20963, P01732, Q13191, P06239 | PRKCQ, PIK3CB, PLCG1, CD3E, CD247, CD8A, CBLB, LCK | More | | Ferrous-fumarate | hsa04662 | B cell receptor signaling pathway | 2.78E-02 | 3 | P42338, P07948, Q8N149 | PIK3CB, LYN, LILRA2 | More | | Ferrous-fumarate | hsa04664 | Fc epsilon RI signaling pathway | 7.30E-04 | 4 | P42338, P07948, P19174, P09917 | PIK3CB, LYN, PLCG1, ALOX5 | More | | Ferrous-fumarate | hsa04666 | Fc gamma R-mediated phagocytosis | 1.73E-02 | 3 | P07948, P42338, P19174 | LYN, PIK3CB, PLCG1 | More | | Ferrous-fumarate | hsa04722 | Neurotrophin signaling pathway | 4.87E-02 | 3 | P42338, P19174, Q92529 | PIK3CB, PLCG1, SHC3 | More | | Ferrous-fumarate | hsa04724 | Glutamatergic synapse | 1.73E-02 | 3 | P63218, P50151, P15104 | GNG5, GNG10, GLUL | More | | Ferrous-fumarate | hsa04725 | Cholinergic synapse | 1.73E-02 | 3 | P63218, P50151, P42338 | GNG5, GNG10, PIK3CB | More | | Ferrous-fumarate | hsa04726 | Serotonergic synapse | 3.41E-02 | 3 | P63218, P50151, P09917 | GNG5, GNG10, ALOX5 | More | | Ferrous-fumarate | hsa04727 | GABAergic synapse | 6.57E-03 | 3 | P63218, P50151, P15104 | GNG5, GNG10, GLUL | More | | Ferrous-fumarate | hsa04730 | Long-term depression | 1.56E-02 | 2 | Q14344, P07948 | GNA13, LYN | More | | Ferrous-fumarate | hsa04750 | Inflammatory mediator regulation of TRP channels | 7.24E-03 | 5 | P14778, P19174, P42338, P24723, Q04759 | IL1R1, PLCG1, PIK3CB, PRKCH, PRKCQ | More | | Ferrous-fumarate | hsa04810 | Regulation of actin cytoskeleton | 2.84E-02 | 7 | P00734, P61586, Q02750, P23229, P26012, P60709, P63261 | F2, RHOA, MAP2K1, ITGA6, ITGB8, ACTB, ACTG1 | More | | Ferrous-fumarate | hsa04910 | Insulin signaling pathway | 4.11E-02 | 3 | Q92529, Q13370, P42338 | SHC3, PDE3B, PIK3CB | More | | Ferrous-fumarate | hsa04914 | Progesterone-mediated oocyte maturation | 2.22E-02 | 3 | P42338, Q13370, P08238 | PIK3CB, PDE3B, HSP90AB1 | More | | Ferrous-fumarate | hsa04915 | Estrogen signaling pathway | 4.76E-03 | 4 | P42338, Q92529, P08238, P11142 | PIK3CB, SHC3, HSP90AB1, HSPA8 | More | | Ferrous-fumarate | hsa04919 | Thyroid hormone signaling pathway | 2.73E-03 | 7 | Q02750, P26678, P60709, P63261, Q09472, P08237, P01106 | MAP2K1, PLN, ACTB, ACTG1, EP300, PFKM, MYC | More | | Ferrous-fumarate | hsa04921 | Oxytocin signaling pathway | 1.22E-02 | 6 | Q02750, P60660, P60709, P63261, P61586, P54284 | MAP2K1, MYL6, ACTB, ACTG1, RHOA, CACNB3 | More | | Ferrous-fumarate | hsa04923 | Regulation of lipolysis in adipocytes | 1.88E-03 | 4 | P07550, Q13370, P42338, Q9Y4H2 | ADRB2, PDE3B, PIK3CB, IRS2 | More | | Ferrous-fumarate | hsa04926 | Relaxin signaling pathway | 1.31E-03 | 5 | P42338, P63218, P50151, P49767, Q92529 | PIK3CB, GNG5, GNG10, VEGFC, SHC3 | More | | Ferrous-fumarate | hsa04931 | Insulin resistance | 3.18E-04 | 3 | Q9Y4H2, P36956, Q13133 | IRS2, SREBF1, NR1H3 | More | | Ferrous-fumarate | hsa04932 | Non-alcoholic fatty liver disease | 4.74E-04 | 3 | Q9Y4H2, P36956, Q13133 | IRS2, SREBF1, NR1H3 | More | | Ferrous-fumarate | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 4.11E-02 | 3 | P42338, P49767, P19174 | PIK3CB, VEGFC, PLCG1 | More | | Ferrous-fumarate | hsa04935 | Growth hormone synthesis, secretion and action | 2.78E-02 | 3 | P19174, P42338, Q92529 | PLCG1, PIK3CB, SHC3 | More | | Ferrous-fumarate | hsa04962 | Vasopressin-regulated water reabsorption | 1.80E-02 | 2 | P62491, P46459 | RAB11A, NSF | More | | Ferrous-fumarate | hsa04966 | Collecting duct acid secretion | 3.44E-02 | 2 | P02730, P00918 | SLC4A1, CA2 | More | | Ferrous-fumarate | hsa04973 | Carbohydrate digestion and absorption | 1.29E-02 | 2 | O43451, P42338 | MGAM, PIK3CB | More | | Ferrous-fumarate | hsa05032 | Morphine addiction | 2.22E-02 | 3 | P63218, P50151, Q13370 | GNG5, GNG10, PDE3B | More | | Ferrous-fumarate | hsa05100 | Bacterial invasion of epithelial cells | 3.64E-02 | 2 | P42338, Q92529 | PIK3CB, SHC3 | More | | Ferrous-fumarate | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 1.00E-04 | 6 | Q16539, P09341, P19875, P19174, P25024, P25025 | MAPK14, CXCL1, CXCL2, PLCG1, CXCR1, CXCR2 | More | | Ferrous-fumarate | hsa05130 | Pathogenic Escherichia coli infection | 1.31E-02 | 8 | P61586, P19338, Q13885, P60709, P63261, Q12933, P00734, O95487 | RHOA, NCL, TUBB2A, ACTB, ACTG1, TRAF2, F2, SEC24B | More | | Ferrous-fumarate | hsa05133 | Pertussis | 1.96E-02 | 3 | P10145, P23528, P0C0L4 | IL8, CFL1, C4A | More | | Ferrous-fumarate | hsa05134 | Legionellosis | 1.29E-02 | 4 | P11215, P11142, P09341, P19875 | ITGAM, HSPA8, CXCL1, CXCL2 | More | | Ferrous-fumarate | hsa05135 | Yersinia infection | 9.76E-03 | 7 | P60709, P63261, P61586, Q16513, P51812, Q12933, Q02750 | ACTB, ACTG1, RHOA, PKN2, RPS6KA3, TRAF2, MAP2K1 | More | | Ferrous-fumarate | hsa05140 | Leishmaniasis | 1.98E-04 | 10 | P13612, O75015, P14598, O60603, P25963, P01375, P29350, P49006, Q16539, Q15080 | ITGA4, FCGR3B, NCF1, TLR2, NFKBIA, TNF, PTPN6, MARCKSL1, MAPK14, NCF4 | More | | Ferrous-fumarate | hsa05146 | Amoebiasis | 2.21E-04 | 8 | P09341, P19875, P14778, P27930, P42338, P11215, P05089, P12814 | CXCL1, CXCL2, IL1R1, IL1R2, PIK3CB, ITGAM, ARG1, ACTN1 | More | | Ferrous-fumarate | hsa05150 | Staphylococcus aureus infection | 3.71E-02 | 6 | P21462, O75015, P59665, P59666, P12838, P49913 | FPR1, FCGR3B, DEFA1; DEFA1B, DEFA3, DEFA4, CAMP | More | | Ferrous-fumarate | hsa05152 | Tuberculosis | 3.04E-02 | 9 | Q13488, O75015, P48382, P25208, O60603, P01375, P10415, P49913, Q9UDY8 | TCIRG1, FCGR3B, RFX5, NFYB, TLR2, TNF, BCL2, CAMP, MALT1 | More | | Ferrous-fumarate | hsa05162 | Measles | 3.91E-02 | 4 | P14784, P07766, P42338, P11142 | IL2RB, CD3E, PIK3CB, HSPA8 | More | | Ferrous-fumarate | hsa05163 | Human cytomegalovirus infection | 1.14E-02 | 5 | P42338, P63218, P50151, Q14344, P30101 | PIK3CB, GNG5, GNG10, GNA13, PDIA3 | More | | Ferrous-fumarate | hsa05164 | Influenza A | 8.79E-03 | 8 | Q09472, P48551, P29728, O15131, Q02750, P60709, P63261, Q9BUJ2 | EP300, IFNAR2, OAS2, KPNA5, MAP2K1, ACTB, ACTG1, HNRPUL1 | More | | Ferrous-fumarate | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 1.14E-02 | 5 | P42338, P63218, P50151, P19174, P07948 | PIK3CB, GNG5, GNG10, PLCG1, LYN | More | | Ferrous-fumarate | hsa05169 | Epstein-Barr virus infection | 3.34E-02 | 5 | P42338, P07948, P30101, Q13761, P07766 | PIK3CB, LYN, PDIA3, RUNX3, CD3E | More | | Ferrous-fumarate | hsa05170 | Human immunodeficiency virus 1 infection | 7.03E-03 | 6 | P42338, P63218, P50151, P30101, P19174, P07766 | PIK3CB, GNG5, GNG10, PDIA3, PLCG1, CD3E | More | | Ferrous-fumarate | hsa05200 | Pathways in cancer | 3.05E-02 | 8 | P42338, P08238, P19174, P49767, P63218, P50151, Q14344, P14784 | PIK3CB, HSP90AB1, PLCG1, VEGFC, GNG5, GNG10, GNA13, IL2RB | More | | Ferrous-fumarate | hsa05202 | Transcriptional misregulation in cancer | 8.78E-03 | 10 | Q13315, P14780, P46527, P35226, O60583, P05164, P59665, P59666, P12838, P08246 | ATM, MMP9, CDKN1B, BMI1, CCNT2, MPO, DEFA1; DEFA1B, DEFA3, DEFA4, ELA2 | More | | Ferrous-fumarate | hsa05203 | Viral carcinogenesis | 2.61E-03 | 3 | Q12834, P62807, Q16778 | CDC20, HIST1H2BC, HIST2H2BE | More | | Ferrous-fumarate | hsa05214 | Glioma | 9.49E-03 | 3 | Q92529, P42338, P19174 | SHC3, PIK3CB, PLCG1 | More | | Ferrous-fumarate | hsa05215 | Prostate cancer | 4.87E-02 | 3 | Q9NRA1, P08238, P42338 | PDGFC, HSP90AB1, PIK3CB | More | | Ferrous-fumarate | hsa05218 | Melanoma | 3.64E-02 | 2 | Q9NRA1, P42338 | PDGFC, PIK3CB | More | | Ferrous-fumarate | hsa05219 | Bladder cancer | 2.72E-02 | 2 | P14780, P04637 | MMP9, TP53 | More | | Ferrous-fumarate | hsa05230 | Central carbon metabolism in cancer | 1.09E-03 | 5 | P01106, P09619, Q02750, P19367, P08237 | MYC, PDGFRB, MAP2K1, HK1, PFKM | More | | Ferrous-fumarate | hsa05231 | Choline metabolism in cancer | 1.83E-04 | 8 | Q02750, P42338, P09619, Q9NRA1, O15245, P35790, P19174, P23743 | MAP2K1, PIK3CB, PDGFRB, PDGFC, SLC22A1, CHKA, PLCG1, DGKA | More | | Ferrous-fumarate | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 8.27E-03 | 6 | P42338, P19174, P07766, P20963, P06239, Q04759 | PIK3CB, PLCG1, CD3E, CD247, LCK, PRKCQ | More | | Ferrous-fumarate | hsa05322 | Systemic lupus erythematosus | 3.83E-03 | 2 | P62807, Q16778 | HIST1H2BC, HIST2H2BE | More | | Ferrous-fumarate | hsa05410 | Hypertrophic cardiomyopathy | 1.48E-06 | 9 | Q8IZS8, P54284, P23229, P13612, P26012, P09493, Q8WZ42, P60709, P63261 | CACNA2D3, CACNB3, ITGA6, ITGA4, ITGB8, TPM1, TTN, ACTB, ACTG1 | More | | Ferrous-fumarate | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 1.08E-07 | 8 | Q8IZS8, P54284, P15924, P23229, P13612, P26012, P60709, P63261 | CACNA2D3, CACNB3, DSP, ITGA6, ITGA4, ITGB8, ACTB, ACTG1 | More | | Ferrous-fumarate | hsa05414 | Dilated cardiomyopathy | 6.73E-07 | 10 | Q8IZS8, P54284, P23229, P13612, P26012, P09493, Q8WZ42, P26678, P60709, P63261 | CACNA2D3, CACNB3, ITGA6, ITGA4, ITGB8, TPM1, TTN, PLN, ACTB, ACTG1 | More | | |